Intratumoral administration of TriMix mRNA vaccines, which do not encode tumor-associated antigens, activate CD8α+ DCs and tumor-specific T cells, thereby slowing tumor growth in mouse models [61]. The gene discussed is CD8A; the disease is neoplasm.